Is Beta Drugs Ltd (BETA) a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Beta Drugs Ltd is a good quality company .

Is Beta Drugs Ltd (BETA) undervalued or overvalued?

The key valuation ratios of Beta Drugs Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone .

What is Beta Drugs Ltd (BETA) share price return in the past 10 years?

Data is not available for this company

Is Beta Drugs Ltd (BETA) a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Beta Drugs Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

What is the share price of Beta Drugs Ltd (BETA)?

Company share prices are keep on changing according to the market conditions. The current trading price of Beta Drugs Ltd (BETA) on 01-Jan-1970 05:30:00 at 05:30 is .

What is the market cap of Beta Drugs Ltd (BETA)?

Market capitalization is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 01-Jan-1970 at 05:30, the market cap of Beta Drugs stood at Rs. 1386.04 Cr.

What is the P/E ratio of Beta Drugs?

The latest standalone P/E ratio of Beta Drugs as of 01-Jan-1970 is 89.81.

What is the P/B ratio of Beta Drugs Ltd (BETA)?

The latest standalone P/B ratio of Beta Drugs Ltd (BETA) as of 01-Jan-1970 is 7.38.

What is the 52-week high and low of Beta Drugs Ltd (BETA)?

The 52-week high of Beta Drugs Ltd (BETA) is Rs. 0.00 and the 52-week low is Rs. 0.00.

What is the TTM revenue of Beta Drugs Ltd (BETA)?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Beta Drugs is Rs. 220.20 (Cr.).

Beta Drugs Ltd (BETA) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Beta Drugs Ltd (BETA)
Brand: Beta Drugs

10 Year X-Ray :

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	21.9%	48.9%	28.6%	18.4%	16.9%	15.9%	26.9%	27.9%	27.3%	13.5%	-
Value Creation Index ⓘ	0.6	2.5	1.1	0.3	0.2	0.1	0.9	1.0	1.0	0.0	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	26.4	41.7	50.6	58.1	65.3	79.5	125	158	198	220	220
Sales YoY Gr.	-	57.9%	21.4%	14.8%	12.5%	21.7%	57.1%	26.5%	25.2%	11.4%	-
Adj EPS ⓘ	1.8	7.4	8.1	8.8	7	6.9	14.1	18.6	21.7	18.5	14.8
YoY Gr.	-	308.8%	9.3%	8.5%	-20.2%	-1.3%	104.1%	32%	16.6%	-15.1%	-
BVPS (₹) ⓘ	3.5	9.7	36.2	44.7	55.9	62.8	76.7	95.4	114.9	127.8	180.3
Adj Net Profit ⓘ	1.1	4.6	7.4	8	7.1	7	14.3	18.8	21.9	18.6	15
Cash Flow from Ops. ⓘ	-0.4	4.7	17.1	7.7	6.1	11.6	18.8	10.2	21.2	18	-
Debt/CF from Ops. ⓘ	-22.5	1.7	0.5	1	1.5	0.5	0.4	0.6	0.3	7.1	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	26.6%	27.5%	20.8%	11.4%
Adj EPS ⓘ	29.4%	21.4%	9.4%	-15.1%
BVPSⓘ	49.1%	18%	18.5%	11.2%
Share Price	-	49.6%	19.2%	-21.5%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	69.4	112	37.7	21.7	14.6	11.7	20.2	21.7	20.7	15.2	9.6
Op. Profit Mgn % ⓘ	11.4	18.7	20.4	18.4	18	19.3	20.2	19.8	17	14.3	12.5
Net Profit Mgn % ⓘ	4.3	11.1	14.5	13.7	10.8	8.8	11.4	11.9	11.1	8.5	7
Debt to Equity ⓘ	3.8	1.4	0.2	0.2	0.2	0.1	0.1	0.1	0.1	1	-
Working Cap Days ⓘ	65	99	138	180	211	196	149	157	170	187	0
Cash Conv. Cycle ⓘ	2	26	47	63	73	66	41	49	51	46	0

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 20.82%

Return on Equity has declined versus last 3 years average to 9.60%

Net Profit has been subdued in last 3 years 9.35%

Sales growth is not so good in last 4 quarters at 2.08%

	Standalone	Consolidated
TTM EPS (₹)	14.8	40.7
TTM Sales (₹ Cr.)	220	362
BVPS (₹) ⓘ	180.3	250.7
Reserves (₹ Cr.) ⓘ	177	251
P/BV ⓘ	7.38	5.31
PE ⓘ	89.81	32.68

From the Market
52 Week Low / High (₹)	0.00 / 0.00
All Time Low / High (₹)	- / -
Market Cap (₹ Cr.)	1,386
Equity (₹ Cr.)	10.4
Face Value (₹)	10
Industry PE ⓘ	43.4

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	69.39	103.22	34.73	21	14.63	11.64	20.23	21.66	20.67	12.6
ROCE (%)	21.91	48.91	28.63	18.42	16.85	15.91	26.91	27.93	27.27	13.53
Asset Turnover Ratio	2.27	2.17	1.39	1.01	0.88	0.92	1.23	1.26	1.27	0.89
PAT to CFO Conversion(x)	-0	1.25	2.43	1	0.86	1.71	1.36	0.53	0.95	1.2
Working Capital Days
Receivable Days	31	65.40	90.10	99.90	106.80	95.80	76.30	86.60	86.90	82.10
Inventory Days	28.60	23	18.80	29	35	31.70	23.60	25.60	32.90	40.90
Payable Days	74.60	85	88.40	97.50	101.90	94.60	84.90	93.90	95.90	116.30

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	26	42	51	58	65	79	125	158	198	220
Operating Expenses ⓘ +	23	34	41	48	54	64	100	127	164	189
Manufacturing Costs	0	1	6	7	8	9	12	15	17	22
Material Costs	15	24	27	30	35	43	71	83	112	120
Employee Cost	3	4	1	2	4	5	7	10	11	15
Other Costs ⓘ	5	5	6	8	7	7	10	18	24	32
Operating Profit ⓘ	3	7	9	10	12	15	25	31	34	31
Operating Profit Margin (%)	11.4%	17.5%	18.7%	17.8%	18.0%	19.3%	20.2%	19.8%	17.0%	14.3%
Other Income ⓘ +	0	0	0	0	0	1	1	1	2	6
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	-5
Interest ⓘ	1	1	1	1	1	1	0	1	1	5
Depreciation ⓘ	1	1	2	2	3	5	5	6	5	7
Profit Before Tax ⓘ	1	5	7	7	9	10	20	25	29	21
Tax ⓘ	0	1	0	-0	2	3	6	6	8	5
Profit After Tax	1	4	7	8	7	7	14	19	22	15
PAT Margin (%)	4.3%	10.3%	13.4%	13.3%	10.9%	8.8%	11.4%	11.9%	11.1%	7.0%
Adjusted EPS (₹)	1.8	6.8	7.5	8.5	7.0	6.9	14.1	18.6	21.7	15.3
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	2	6	33	41	56	63	77	96	116	129
Share Capital ⓘ	1	1	9	9	10	10	10	10	10	10
Reserves ⓘ	1	5	24	32	47	54	68	87	106	119
Debt +	8	8	6	6	7	4	5	4	4	124
Long Term Debt	4	4	3	5	3	3	5	4	4	124
Short Term Debt	4	4	4	1	4	1	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	4	7	6	10	9	13	20	23	36	41
Others Liabilities ⓘ	1	3	4	9	10	8	12	14	20	28
Total Liabilities ⓘ	15	23	50	66	83	89	115	137	175	321
Fixed Assets
Net Fixed Assets ⓘ +	7	8	13	12	32	28	34	35	36	53
Gross Block	9	11	18	19	42	43	54	60	65	90
Accumulated Depreciation	2	3	5	7	10	15	20	25	29	36
CWIP ⓘ	0	0	1	15	0	2	0	0	0	0
Investments ⓘ	0	0	0	2	6	7	7	7	6	6
Inventories	3	2	3	6	6	8	8	14	22	27
Trade Receivables	4	11	14	17	21	21	31	44	50	49
Cash Equivalents ⓘ	0	0	12	3	4	8	16	18	27	142
Others Assets ⓘ	0	2	6	10	14	15	19	21	33	44
Total Assets ⓘ	15	23	50	66	83	89	115	137	175	321

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	-0	5	17	8	6	12	19	10	21	18
PBT ⓘ	1	5	7	7	9	10	20	25	29	25
Adjustment ⓘ	2	2	15	2	2	4	3	0	-6	-8
Changes in Working Capital ⓘ	-3	-3	-5	-1	-4	-2	-5	-15	-2	0
Tax Paid ⓘ	-0	0	0	0	0	0	0	0	0	0
Cash Flow From Investing Activity ⓘ +	-2	-2	-11	-16	-14	-3	-13	-6	-11	-21
Capex	-2	-2	-8	-15	-8	-3	-10	-7	-6	-24
Net Investments	0	0	0	-2	-5	-0	0	-0	1	0
Others ⓘ	0	0	-3	0	-2	1	-3	1	-5	3
Cash Flow From Financing Activity ⓘ +	3	-3	5	-1	9	-4	1	-2	-1	118
Net Proceeds from Shares ⓘ	0	0	8	0	9	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	0	-1	-1	3	-1	-0	2	-1	0	123
Interest Paid ⓘ	-1	-1	-1	-1	-1	-1	-0	-1	-1	-5
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	3	-1	-0	-2	3	-3	-1	0	0	-0
Net Cash Flow ⓘ	0	0	12	-9	1	4	7	2	9	115

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Beta Drugs Ltd (BETA) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating